MRTX News and Press, Mirati Therapeutics Inc. From 06/27/19

SAN DIEGO , June 27, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 2,415,000 shares of its common stock at a public offering price of $97 .00 per share. This includes the exe...

Mirati Therapeutics (NASDAQ: MRTX ) prices its public offering of 2.1M common shares at $97 per share. Underwriters over-allotment is an additional 315K shares. Closing date is June 27. More news on: Mirati Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ......

SAN DIEGO , June 25, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 2,100,000 shares of its common stock at a price to the public of $97.00 per share. The aggregate gross proceeds from this offering ar...

SAN DIEGO , June 24, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Mirati. In addition, Mirati expects to grant the underwriters...

Biotech Pulse Biotech shares are up this year, as represented by the Nasdaq Biotechnology Index ( IBB ), which is the industry benchmark, and the S&P Select Biotechnology Index ( XBI ), after a sharp decline in 2018. This is a welcome respite for biotech investors. However, it has not ...

Buy a stock the way you would buy a house. Understand and like it such that you'd be content to own it in the absence of any market. - Warren Buffett I recently featured an analysis of intriguing innovators that were recommended during the IBI Expert interview conducted in 2017. Going ...

Mirati Therapeutics ( MRTX ) shares surged recently, mainly because of positive data that stemmed from Amgen ( AMGN ). That's because Amgen reported positive results from its Phase 1 study using its drug AMG 510. The reason why the stock of Mirati traded higher is because Amgen established...

Shares of Mirati Therapeutics ( MRTX ) have risen by over 800% since my September 2017 article called the stock a Buy and noted it was poised to capitalize on the emerging theme of targeted oncology (much like prior picks in the space Loxo Oncology and Ignyta). A couple months later, I encou...

Preliminary data from an open-label Phase 1 clinical trial evaluating Amgen's (NASDAQ: AMGN ) KRAS G12C  inhibitor AMG 510 in patients with solid tumors showed a positive effect. The data were presented at ASCO in Chicago. More news on: Amgen Inc., Mirati Therapeutics, Inc., Health...

Castor Maritime (NASDAQ: CTRM ) +112%  on 1H results . More news on: Castor Maritime Inc., Attis Industries, Inc., Proteostasis Therapeutics, Inc., Stocks on the move, Read more ...